Truist analyst Richard Newitter raised the firm’s price target on Stryker (SYK) to $380 from $370 and keeps a Hold rating on the shares. The company posted a “solid” Q3 organic revenue beat and boasts one of the better growth profiles in large cap MedTech, with several new launch areas set to build momentum into Q4 and FY25, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: